Phase I dose-escalation study of oral administration of the Histone Deacetylase (HDAC) Inhibitor S 78454 given in combination with a fixed dose infusion of Cisplatin in patients with advanced solid tumours
Latest Information Update: 02 Mar 2022
At a glance
- Drugs Abexinostat (Primary) ; Cisplatin
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors IRIS
- 21 Nov 2014 Interim efficacy and safety results presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
- 16 Feb 2014 New trial record